<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00456560</url>
  </required_header>
  <id_info>
    <org_study_id>AV650-019</org_study_id>
    <nct_id>NCT00456560</nct_id>
  </id_info>
  <brief_title>AV650 Drug-Drug Interaction Study</brief_title>
  <official_title>A Phase I, Randomized, Two-Period, Single-Center Study to Assess the Effect of CYP2D6 and CYP2C19 Inhibitors on a Single Oral Dose of AV650 (300 mg) in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avigen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Avigen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects that paroxetine and fluvoxamine have on
      the way the body distributes, breakdowns and eliminates AV650. In addition, information about
      any side effects that may occur will also be collected.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of AV650</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of AV650</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genetic contribution, if any, to AV650 metabolism</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AV650</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluvoxamine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paroxetine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI between 18.5 to 29.9 kg/m2

          -  In good health, determined by no clinically significant findings from medical history,
             12-lead ECG, and vital signs

          -  Clinical laboratory evaluations within the reference range for the test laboratory

          -  Negative test for selected drugs of abuse at Screening

          -  Negative HBsAg and HIV antibody screens

          -  Females of childbearing potential must be surgically sterile, post-menopausal for at
             least one year, or using and effective method of contraception; females of child
             bearing potential must have a negative serum pregnancy test at Screening and Day -1

          -  Males must be either sterile or agree to use an approved method of contraception

          -  Able to comprehend and willing to sign an Informed Consent Form

        Exclusion Criteria:

          -  History or clinical manifestations of significant metabolic, hepatic, renal,
             hematological, pulmonary, cardiovascular, endocrine, gastrointestinal, urological,
             neurological, psychiatric disorders, or cancer

          -  History of inflammatory arthritis

          -  History of symptomatic hypotension

          -  History of severe physical injury, direct impact trauma, or neurological trauma within
             6 months

          -  History of seizure disorders

          -  History of bipolar or major depressive disorder

          -  History of hypersensitivity or allergies to any drug compound

          -  Known intolerance to benzodiazepines

          -  Known intolerance to active and/or inactive ingredients in fluvoxamine or paroxetine

          -  History of stomach or intestinal surgery or resection, except that appendectomy,
             hernia repair, and/or cholecystectomy will be allowed

          -  History or presence of an abnormal ECG

          -  History of alcoholism, drug abuse, or drug addiction

          -  Use of any nicotine-containing or nicotine-replacement products within 6 months of Day
             -1

          -  Participation in any other investigational study drug trial within 90 days of Day -1

          -  Use of any prescription medications/products within 3 months of Day 1 unless deemed
             acceptable by the PI

          -  Received any vaccination or immunization within 1 month of Day -1

          -  Use of any over-the-counter, non-prescription preparations within 7 days of Day -1

          -  Use of alcohol-containing, grapefruit-containing, or caffeine-containing foods or
             beverages with 72 hours of Day -1

          -  Poor peripheral venous access

          -  Donation of blood within 3 months of Day -1 or of plasma within 2 weeks of Screening

          -  Receipt of blood products within 2 months of Day 1

          -  Female subjects who are pregnant or nursing

          -  Any acute or chronic condition that, in the opinion of the PI, would limit the
             subject's ability to complete and/or participate in this clinical study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Covance Global Clinical Pharmacology Inc.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2007</study_first_submitted>
  <study_first_submitted_qc>April 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2007</study_first_posted>
  <last_update_submitted>September 13, 2007</last_update_submitted>
  <last_update_submitted_qc>September 13, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2007</last_update_posted>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paroxetine</mesh_term>
    <mesh_term>Fluvoxamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

